🔥🐔 BizChicken 🐔🔥
Companies Similar to Checkpoint Therapeutics, Inc.
Sign Up Today!
Sign up for BizChicken and discover more about the corporations around you.
Candel Therapeutics, Inc.
CAN-2409, CAN-3110
Candel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing immunotherapies for cancer patients, with products like CAN-2409 and CAN-3110 in various clinical trial phases.
About | About | About | About | Contact | Careers | Careers | About | About | About | Careers | About
Symbol: CADL
Recent Price: $7.95
Industry: Biotechnology
CEO: Dr. Paul-Peter Tak FOCIS, M.D., Ph.D.
Sector: Healthcare
Employees: 42
Address: 117 Kendrick Street, Needham, MA 02494
Phone: 617 916 5445
Last updated: 2024-12-31
CERo Therapeutics Holdings, Inc.
Engineered T Cell Therapeutics
CERo Therapeutics Holdings, Inc. is an immunotherapy company focused on developing engineered T cell therapeutics for cancer treatment, particularly targeting hematologic malignancies using innovative immune system integration strategies.
Symbol: CERO
Recent Price: $0.06
Industry: Biotechnology
CEO: Mr. Christopher B. Ehrlich M.B.A.
Sector: Healthcare
Employees: 8
Address: 201 Haskins Way, South San Francisco, CA 94080
Phone: 650-407-2376
Last updated: 2024-12-31
Elicio Therapeutics, Inc.
ELI-002
Elicio Therapeutics is a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for cancer and other diseases, with its lead product ELI-002 targeting KRAS-driven cancers.
Symbol: ELTX
Recent Price: $5.00
Industry: Biotechnology
CEO: Mr. Robert T. Connelly
Sector: Healthcare
Employees: 32
Address: 451 D Street, Boston, MA 02210
Phone: 857-209-0050
Last updated: 2024-12-31
Fate Therapeutics, Inc.
programmed cellular immunotherapies
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its development programs include various NK- and T-cell immuno-oncology therapies targeting different cancers.
Vision/Values | About | Management | Directors | About | Contact
Symbol: FATE
Recent Price: $1.62
Industry: Biotechnology
CEO: Mr. J. Scott Wolchko
Sector: Healthcare
Employees: 181
Address: 12278 Scripps Summit Drive, San Diego, CA 92131
Phone: 858 875 1800
Leadership
- William Rastetter, Ph.D., Chairman
- John Mendlein, Ph.D., J.D., Vice Chairman
- Dr. Shefali Agarwal, Board Member
- Timothy P. Coughlin, Board Member
- Robert S. Epstein, M.D., Board Member
- Karin Jooss, Ph.D., Board Member
- Michael Lee, Board Member
- Neely Mozaffarian, M.D., Ph.D., FACR, Board Member
- Yuan Xu, Ph.D., Board Member
- Scott Wolchko, President & CEO
Last updated: 2024-12-31
Omeros Corporation
Narsoplimab
Omeros Corporation is a commercial-stage biopharmaceutical company that focuses on discovering, developing, and commercializing therapeutics for inflammation, immune-related cancers, and addictive disorders.
Symbol: OMER
Recent Price: $9.74
Industry: Biotechnology
CEO: Dr. Gregory A. Demopulos M.D.
Sector: Healthcare
Employees: 198
Address: The Omeros Building, Seattle, WA 98119
Phone: 206 676 5000
Last updated: 2024-12-31
Oncternal Therapeutics, Inc.
zilovertamab, ONCT-216, ONCT-808, ONCT-534
Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in oncology therapies for cancers with significant unmet medical needs, featuring a pipeline that includes the monoclonal antibody zilovertamab and various other targeted treatments.
Symbol: ONCT
Recent Price: $0.53
Industry: Biotechnology
CEO: Dr. James B. Breitmeyer M.D., Ph.D.
Sector: Healthcare
Employees: 27
Address: 12230 El Camino Real, San Diego, CA 92130
Phone: 858 434 1113
Last updated: 2024-12-31
BioXcel Therapeutics, Inc.
IGALMI
Bio Xcel Therapeutics, Inc. is a biopharmaceutical company leveraging artificial intelligence for developing transformative medicines in neuroscience and immuno-oncology. It focuses on re-innovating existing drugs with machine learning to identify new therapeutic uses.
Symbol: BTAI
Recent Price: $0.37
Industry: Biotechnology
CEO: Dr. Vimal D. Mehta Ph.D.
Sector: Healthcare
Employees: 74
Address: 555 Long Wharf Drive, New Haven, CT 06511
Phone: 475 238 6837
Last updated: 2024-12-31
Checkpoint Therapeutics, Inc.
Cosibelimab
Checkpoint Therapeutics, Inc. is a clinical-stage immunotherapy and targeted oncology company focused on acquiring, developing, and commercializing novel treatments for solid tumor cancers. Their lead product candidates include Cosibelimab, a fully-human monoclonal antibody, and other treatments for various cancer targets.
Symbol: CKPT
Recent Price: $3.35
Industry: Biotechnology
CEO: Mr. James F. Oliviero III, C.F.A.
Sector: Healthcare
Employees: 23
Address: 95 Sawyer Road, Waltham, MA 02453
Phone: 781 652 4500
Last updated: 2024-12-31
Celldex Therapeutics, Inc.
therapeutic monoclonal and bispecific antibodies
Celldex Therapeutics is a biopharmaceutical company focused on developing therapeutic monoclonal and bispecific antibodies for treating inflammatory diseases and cancers.
About | About | Management | Directors | About | Contact | About | Contact | Careers | Careers | Careers | Careers | Jobs | Careers | About | About
Symbol: CLDX
Recent Price: $25.12
Industry: Biotechnology
CEO: Mr. Anthony S. Marucci M.B.A.
Sector: Healthcare
Employees: 160
Address: Perryville III Building, Hampton, NJ 08827
Phone: 908 200 7500
Leadership
- Anthony S. Marucci, Founder, President, Chief Executive Officer and Director
- Tibor Keler, Ph.D., Founder, Executive Vice President and Chief Scientific Officer
- Diane C. Young, M.D., Senior Vice President and Chief Medical Officer
- Elizabeth Crowley, Senior Vice President, Chief Product Development Officer
- Sam Martin, Senior Vice President and Chief Financial Officer
- Ronald A. Pepin, Ph.D., Senior Vice President and Chief Business Officer
- Richard Wright, Ph.D., Senior Vice President and Chief Commercial Officer
- Sarah Cavanaugh, Senior Vice President, Corporate Affairs and Administration
- Margo Heath-Chiozzi, M.D., Senior Vice President, Regulatory Affairs
- Freddy A. Jimenez, Esq., Senior Vice President and General Counsel
- Karen L. Shoos, J.D., Former Chair, Director of Operations, Maryland Tech Council Venture Mentoring Services Program
- Keith L. Brownlie, Former Partner, Ernst & Young LLP
- Herbert J. Conrad, Former President, Roche Pharmaceuticals US
- James J. Marino, J.D., Former Partner, Dechert LLP
- Harry H. Penner, Jr., J.D., L.L.M., Former Chairman and CEO, Nascent Bioscience
- Cheryl L. Cohen, President, CLC Consulting; Former Chief Commercial Officer of Medivation, Inc.
- Dr. Garry Neil, Chief Executive Officer; Chair of the Board, Avalo Therapeutics
- Rita Jain, M.D., Former Executive Vice President, Chief Medical Officer of ChemoCentryx, Inc.
- Carl June, M.D.,
- Michel Nussenzweig, M.D., Ph.D.,
- Marc E. Rothenberg M.D., Ph.D.,
- Joseph Schlessinger, Ph.D.,
- Louis Weiner, M.D.,
Last updated: 2024-12-31
Compass Therapeutics, Inc.
CTX-009, CTX-471, CTX-8371
Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing antibody-based therapeutics to treat various human diseases. Their clinical stage products include investigational bispecific antibodies like CTX-009 and monoclonal antibodies such as CTX-471.
Symbol: CMPX
Recent Price: $1.48
Industry: Biotechnology
CEO: Dr. Thomas J. Schuetz M.D., Ph.D.
Sector: Healthcare
Employees: 32
Address: 80 Guest Street, Boston, MA 02135
Phone: 617 500 8099
Last updated: 2024-12-31
Cogent Biosciences, Inc.
CGT9486
Cogent Biosciences, Inc. is a biotechnology company focused on developing precision therapies for genetically defined diseases, with lead product candidate CGT9486 targeting mutations driving systemic mastocytosis and advanced gastrointestinal stromal tumors.
Symbol: COGT
Recent Price: $7.67
Industry: Biotechnology
CEO: Mr. Andrew R. Robbins M.B.A.
Sector: Healthcare
Employees: 164
Address: 200 Cambridge Park Drive, Cambridge, MA 02140
Phone: 617 945 5576
Last updated: 2024-12-31
Corvus Pharmaceuticals, Inc.
Mupadolimab (CPI-006)
Corvus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing immuno-oncology therapies, including Mupadolimab for non-small cell lung cancer, CPI-818 for T-cell lymphomas, and Ciforadenant for renal cell cancer.
Symbol: CRVS
Recent Price: $5.25
Industry: Biotechnology
CEO: Dr. Richard A. Miller M.D.
Sector: Healthcare
Employees: 28
Address: 863 Mitten Road, Burlingame, CA 94010
Phone: 650 900 4520
Last updated: 2024-12-31
Cue Biopharma, Inc.
CUE-101
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company developing biologic drugs to modulate the human immune system for treating cancers, chronic infectious diseases, and autoimmune disorders.
About | Leadership | About | Directors | About | Contact | About | About | About | Careers | Careers | Careers | Careers | Careers | About
Symbol: CUE
Recent Price: $1.02
Industry: Biotechnology
CEO: Mr. Daniel R. Passeri J.D., M.Sc.
Sector: Healthcare
Employees: 53
Address: 21 Erie Street, Cambridge, MA 02139
Phone: 617 949 2680
Leadership
- Dan Passeri, Chief Executive Officer
- Anish Suri, President and Chief Scientific Officer
- Lucinda Warren, Chief Business Officer
- Matteo Levisetti, Chief Medical Officer
- Kerri-Ann Millar, Chief Financial Officer
- Colin Sandercock, Senior Vice President and General Counsel
- Frank Morich, M.D., Ph.D., Chairman of the Board
- Dan Passeri, M.Sc., J.D., Chief Executive Officer
- Peter Kiener, D.Phil.,
- Fred Driscoll,
- Patrick Verheyen,
- Pamela D. Garzone, Ph.D.,
Last updated: 2024-12-31
Elevation Oncology, Inc.
seribantumab
Elevation Oncology, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for the treatment of cancer in genomically defined patient populations. Their lead program is seribantumab, an anti-HER3 monoclonal antibody for advanced solid tumors.
Symbol: ELEV
Recent Price: $0.57
Industry: Biotechnology
CEO: Mr. Joseph J. Ferra Jr.
Sector: Healthcare
Employees: 29
Address: 888 Seventh Avenue, New York, NY 10106
Phone: 716 371 1125
Last updated: 2024-12-31
Immunome, Inc.
IMM-ONC-01, IMM-BCP-01
Immunome, Inc. is a biopharmaceutical company focused on developing antibody therapeutics for oncology and infectious diseases, offering innovative solutions such as IMM-ONC-01 for cancer and IMM-BCP-01 for COVID-19 treatment.
Symbol: IMNM
Recent Price: $10.28
Industry: Biotechnology
CEO: Dr. Clay B. Siegall Ph.D.
Sector: Healthcare
Employees: 78
Address: 665 Stockton Drive, Exton, PA 19341
Phone: 610 321 3700
Last updated: 2024-12-31
Immuneering Corporation
IMM-1-104 and IMM-6-415
Immuneering Corporation is a biopharmaceutical company focused on developing oncology and neuroscience product candidates, with key products like IMM-1-104 for cancer treatment and IMM-6-415 for solid tumors.
Symbol: IMRX
Recent Price: $2.25
Industry: Biotechnology
CEO: Dr. Benjamin J. Zeskind M.B.A., Ph.D.
Sector: Healthcare
Employees: 66
Address: 245 Main Street, Cambridge, MA 02142
Phone: 617 500 8080
Last updated: 2024-12-31
Immunovant, Inc.
batoclimab
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases, including batoclimab for myasthenia gravis and thyroid eye disease.
Symbol: IMVT
Recent Price: $23.88
Industry: Biotechnology
CEO: Dr. Peter Salzmann M.B.A., M.D.
Sector: Healthcare
Employees: 207
Address: 320 West 37th Street, New York, NY 10018
Phone: 917 580 3099
Leadership
- Pete Salzmann, M.D., MBA, Chief Executive Officer
- Renee Barnett, MBA, Chief Financial Officer
- Christine Blodgett, Senior Vice President of Human Resources
- Andy Deig, Senior Vice President Strategic Finance
- Michael Geffner M.D., MBA, Chief Medical Officer
- Julie Kirschling, Senior Vice President, Program and Alliance Management
- Mark Levine, Chief Legal Officer and Corporate Secretary
- Bill Macias, M.D., Ph.D., Chief Medical Officer
- Becky Merlina, Senior Vice President, Global Head of Quality
- Jody Roth, MS, RAC, PMP, Senior Vice President, Regulatory Affairs
- Jay S. Stout, PhD, Chief Technology Officer
- Yan Zheng, Ph.D., Senior Vice President Biostatistics, Programming & Data Management
- Chandra Adams, Vice President, Associate General Counsel
- Maria Alba, M.D., Vice President of Clinical Development
- Farah Ali, Vice President, Clinical Development
- Jennifer Ashley, Vice President, Associate General Counsel
- Annetta Beauregard, Vice President, Regulatory Affairs Strategy
- Harry Berlanga, MSc., VP, CMC & Distribution Quality
- Ranjit Deshmukh, Ph.D., Vice President of CMC and Technical Operations
- Scott Forman, MBA, Vice President, Program Management
- Tom Forman, MBA, Vice President, CMC Project Management
- Ian Gourley, M.D., Vice President of Clinical Development
- Thomas Hardy, M.D., Ph.D., Vice President of Drug Safety and Pharmacovigilance
- Laci Hasenour, Vice President Marketing, Neurology
- Aileen Ilaria, MBA, Vice President, Clinical Operations – Global Site Management
- Claudia Jacobs, Ph.D., Vice President of CMC Project Management Operations and Clinical Supply
- Jonathan Janes, MB, Vice President Clinical Development
- Ant Kidwell, Vice President of IT and Facilities
- Chedvi Levin-Sister, Vice President of Finance
- Launi Masterson, Vice President of Clinical Operations
- Andy Minke, Vice President Program Management
- Linda McKerral, Vice President, CMC Analytical Sciences
- Pooja Mehta, Vice President Drug Substance Tech Transfer
- Regina Mirra, VP, Regulatory Operational Excellence
- Jennifer Moseley, Vice President of Clinical Operations
- Sheetal Patel M.D., MS MBA, Vice President of Clinical Development
- Cassandra Pauyo, Vice President, Data Management
- Rod Saponjic Ph.D., MBA, Vice President of Clinical Operations
- Lauren Schrier, MBA, Vice President of Marketing
- Frank Torti, M.D., Chairperson of Board of Directors
- Andrew Fromkin, Member of Board of Directors
- Douglas Hughes, Member of Board of Directors
- George Migausky, Member of Board of Directors
- Atul Pande, M.D., Member of Board of Directors
- Eric Venker, M.D., Pharm.D., Member of Board of Directors
Last updated: 2024-12-31
TG Therapeutics, Inc.
Ublituximab, Umbralisib, Cosibelimab, TG-1701, TG-1801
TG Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on developing and commercializing novel treatments for B-cell malignancies and autoimmune diseases.
About | About | Leadership | About | About | About | About | Our Story | Contact | Contact | About | About
Symbol: TGTX
Recent Price: $31.45
Industry: Biotechnology
CEO: Mr. Michael S. Weiss Esq.
Sector: Healthcare
Employees: 264
Address: 2 Gansevoort Street, New York, NY 10014
Phone: 212 554 4484
Leadership
- Michael S. Weiss, Chairman, President, and Chief Executive Officer
- Sean A. Power, CPA, Chief Financial Officer
- Adam Waldman, Chief Commercialization Officer
Last updated: 2024-12-31
Xilio Therapeutics, Inc.
XTX101
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients with a focus on tumor-selective therapies.
Symbol: XLO
Recent Price: $0.97
Industry: Biotechnology
CEO: Dr. Rene Russo BCPS, Pharm.D.
Sector: Healthcare
Employees: 73
Address: 828 Winter Street, Waltham, MA 02451
Phone: 617 430 4680
Last updated: 2024-12-31
Cullinan Oncology, Inc.
CLN-081
Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. Their lead candidate, CLN-081, is in a trial for treating non-small cell lung cancer. The company also has several preclinical products targeting various forms of cancer.
Symbol: CGEM
Recent Price: $12.20
Industry: Biotechnology
CEO: Mr. Nadim Ahmed
Sector: Healthcare
Employees: 85
Address: One Main Street, Cambridge, MA 02142
Phone: 617 410 4650
Last updated: 2024-12-31